Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: A success story

Vaccine

Volumn 20, Issue SUPPL. 1, 2001, Pages

  Miller, E ^a   Salisbury, D ^b   Ramsay, M ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b Immunisation Infectious Disease Group   (United Kingdom)

Author keywords

Meningococcal conjugate vaccine; Meningococcal serogroup C disease

Indexed keywords

ANTIBODY CONJUGATE; DIPHTHERIA VACCINE; MENINGOCOCCUS VACCINE; TETANUS TOXOID;

ADOLESCENT; ARTICLE; ASSAY; CHILD; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HEALTH CARE PLANNING; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFANT; LICENSING; MEDICAL RESEARCH; PRIORITY JOURNAL; REGISTRATION; SEROTYPE; UNITED KINGDOM; VACCINATION; VACCINE PRODUCTION;

GREAT BRITAIN; HUMANS; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; VACCINATION;

EID: 0035888124     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00299-7     Document Type: Article

References (32)

1. Evaluation of the Applied Biosystems Automated Taqman PCR system for the detection of meningococcal DNA
2. Control of meningococcal disease: Guidance for microbiologists
3. Changing patterns of case ascertainment and trends in meningococcal disease in England and Wales
4. Enhanced surveillance of suspected meningococcal disease
5. Enhanced surveillance of suspected meningococcal disease
6. Reactogenicity and immunogenicity of conjugate meningococcal serogroup A and C vaccine in England infants
7. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory
8. Induction of immunological memory in UK infants by a meningococcal A/C conjugate vaccine
9. Evaluation of de-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: Reactogenicity, immunogenicity, immunologic priming and bactericidal activity against O-acetylated and de-O-acetylated serogroup C strains
10. 197-conjugate vaccines
11. Monitoring stability of meningococcal group C conjugate vaccines; correlation of physicochemical methods and immunogenicity assays
12. 197-conjugate vaccines
13. Human immunity to the meningococcus. I. The role of humoral antibodies
14. Serological basis for use of meningococcal serogroup C conjugate vaccines in the UK: A re-evaluation of correlates of protection
15. Recent developments in bacterial conjugate vaccines
16. Prevalence of de-O-acetylated serogroup C meningococci before the introduction of meningococcal serogroup C conjugate vaccines in the UK
17. Ability of three different meningococcal C conjugate vaccines to induce immunological memory after a single dose in UK toddlers
18. Influence of prior meningococcal C polysaccharide vaccine on the response and generation of memory following meningococcal C conjugate vaccine in young children
19. Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine
20. Comparison of antibody kinetics following meningococcal serogroup C conjugate vaccine between healthy adults previously vaccinated with meningococcal A/C polysaccharide vaccine and vaccine-naive controls
21. Immunogenicity and reactogenicity of a group C meningococcal conjugate vaccine compared with a group A+C meningococcal polysaccharide vaccine in adolescents in a randomised observer-blind controlled trial
22. Safety, immunogenicity and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants. A randomised controlled trial
23. Safety and immunogenicity of three lots of meningococcal serogroup C conjugate vaccine administered at 2-4 months of age
24. A randomized, double-blind, controlled trial of the immunogenicity and tolerability of a meningococcal serogroup C conjugate vaccine in young British infants
25. COVER programme: October to December 1999. Vaccination coverage statistics for children up to 5 years of age in the UK
26. Meningitis C immunisation is low among young people who are not in education
27. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England
28. The Stonehouse survey: Nasopharyngeal carriage of meningococci and Neisseria lactamica
29. Importance of complement source in measuring meningococcal bactericidal titers
30. Safety of meningococcal group C conjugate vaccines
31. Safety assessment post-licensure